417721-79-0

Basic information

• Product Name: 4-(4-AMINOPHENOXY)-7-AZAINDOLE
• Synonyms: 4-(4-AMINOPHENOXY)-7-AZAINDOLE
• CAS NO: 417721-79-0
• Molecular Formula: C₁₃H₁₁N₃O
• Molecular Weight: 225.25
• Mol File: 417721-79-0.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-AMINOPHENOXY)-7-AZAINDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-AMINOPHENOXY)-7-AZAINDOLE(417721-79-0)
• EPA Substance Registry System: 4-(4-AMINOPHENOXY)-7-AZAINDOLE(417721-79-0)

Safety Data

• Hazardous Substances Data: 417721-79-0(Hazardous Substances Data)

Upstream product

• 55052-24-9 1H-Pyrrolo[2,3-b]pyridine-7-oxide 
• 924909-09-1 1-benzyloxymethyl-4-chloro-1H-pyrrolo[2,3-b]pyridine 
• 271-63-6 7-Azaindole 
• 924909-10-4 4-(1-benzyloxymethyl-1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline 
• 123-30-8 4-amino-phenol 
• 55052-28-3 4-chloro-7-azaindole 
• 417721-78-9 4-(4-nitrophenoxy)-1H-pyrrolo[2,3-b]pyrimidine 
• 100-02-7 4-nitro-phenol 
• 7439-89-6 iron 

Downstream Products

• 924908-32-7 1-[4-(2-methoxyethoxy)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea 

Relevant articles and documents

Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity against VEGFR2, p38α, and B-Raf

A series of diarylurea inhibitors of the cardiac-specific kinase TNNI3K were developed to elucidate the biological function of TNNI3K and evaluate TNNI3K as a therapeutic target for the treatment of cardiovascular diseases. Utilizing a structure-based design, enhancements in kinase selectivity were engineered into the series, capitalizing on the established X-ray crystal structures of TNNI3K, VEGFR2, p38α, and B-Raf. Our efforts culminated in the discovery of an in vivo tool compound 47 (GSK329), which exhibited desirable TNNI3K potency and rat pharmacokinetic properties as well as promising kinase selectivity against VEGFR2 (40-fold), p38α (80-fold), and B-Raf (>200-fold). Compound 47 demonstrated positive cardioprotective outcomes in a mouse model of ischemia/reperfusion cardiac injury, indicating that optimized exemplars from this series, such as 47, are favorable leads for discovering novel medicines for cardiac diseases.

Synthesis and antiproliferative activity of pyrrolo[2,3-b]pyridine derivatives bearing the 1,8-naphthyridin-2-one moiety

A series of pyrrolo[2,3-b]pyridine derivatives bearing the 1,8-naphthyridin-2-one moiety were synthesized, and evaluated for their antiproliferative activity against four cancer cell lines (HT-29, A549, H460, and U87MG) and six tyrosine kinases (c-Met, Flt-3, PDGFR-β VEGFR-2, EGFR, and c-Kit) inhibitory activities in vitro. Most compounds showed moderate to excellent potency, with the most promising analogue 32 showing Flt-3/c-Met IC50 value of 1.16/1.92 nM. Structure-activity relationship studies indicated that the hydrogen atom served as R1 group was benefited to the potency, and mono-electron-withdrawing groups (mono-EWGs) on the phenyl ring (such as R3 = 4-F) showed a higher preference for antiproliferative activity.

Preparation and application of pyridoheterocycle compound with 1-aryl-4-oxy-1,4-dihydroquinoline structure

The invention relates to preparation and application of a pyridoheterocycle compound with a 1-aryl-4-oxy-1,4-dihydroquinoline structure as shown in general formula I, as well as pharmaceutically acceptable salt, hydrate, solvate and prodrugs thereof. The substituted groups are R, R1, X, Y and Z. The invention further relates to a compound as shown in the general formula I having a strong effect ofinhibiting c-Met kinase, and application of the compounds, pharmaceutically acceptable salt, hydrate, solvate and prodrugs thereof in preparation of medicines for treating diseases caused by abnormally activated high expression of c-Met kinase, particularly application in preparation of medicines for treating and/or preventing cancers.